Biography
Petrina Kamya, Ph.D., is the Global Business Development Director for Insilico Medicine’s end-to-end AI-driven drug discovery platform, Pharma. AI. Before joining Insilico, Dr. Kamya was at Chemical Computing Group (CCG) and Certara. At CCG, she led the sales and business development of molecular modeling software for pharma and biotech companies and academia. At Certara, she consulted with pharma companies on Market Access strategy. During the pandemic, investment banks and management consulting firms turned to Dr. Kamya to provide due diligence on AI-driven drug discovery platform companies. She became very familiar with many of the key players in the space. She saw the potential these companies, including InSilico Medicine, could have in the optimization of the drug discovery and development process. She joined the InSilico Medicine team in August 2020, where she works closely with drug discovery stakeholders interested in implementing AI-driven computer-aided techniques into their discovery pipelines.

Biography
Jim Edwards is currently leading a multi-disciplinary group of computational & data scientists providing predictive and design tools across all modalities within the Therapeutics Discovery organization at Janssen, starting at project inception through the identification of clinical candidates. Primary to this, Jim was US Regional Head, Discovery Chemistry at Janssen Research & Development, leading drug discovery teams in South Francisco & La Jolla CA, Boston, MA, and Spring House, PA. These teams were responsible for the design and synthesis of small molecule drug candidates working with partners across DPDS and all six Therapeutic Areas within JRD. From 1999-2014, Jim led various Immunology medicinal chemistry groups at Janssen which delivered clinical-stage molecules against multiple novel first-in-class targets. Jim received his Ph.D. from the University of Illinois, Urbana-Champaign, working with Professor Scott Denmark, and performed post-doctoral studies with Professor Lanny Liebeskind at Emory University.

Biography
Dr. Tommaso Mansi is currently leading the AI/ML and Digital Health team at the Janssen R&D Data Science division. Dr. Mansi’s focus is on the development of AI solutions that enable deriving actionable insights from multimodal, multiscale data, to support and help accelerate drug discovery and development. Prior to joining Janssen, Dr. Mansi was at Siemens Healthineers, Digital Technology and Innovation. Dr. Mansi’s research interests cover artificial intelligence in healthcare, medical imaging, computational physiology, AI for biology, and image-guided therapy. Dr. Mansi received several awards for his work, gave multiple keynotes at international conferences and events. He holds 60+ granted US patents, co-edited 1 monograph and co-authored 100+ scientific publications.

Biography
Martin-Immanuel Bittner is the CEO of Arctoris, a biotech company combining wet lab automation and machine learning for accelerated small molecule drug discovery. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford, where he co-founded Arctoris. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including EACR, AACR, and ESTRO. Martin is a Fellow of the RSA and an elected member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.